Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

Fig. 1

Trial design

BcR: Biochemical recurrence; OligoM + : oligometastatic disease; PSMA PET-CT/MRI: prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI); T: testosterone; PSA: prostate specific antigen; M1a: non-regional lymph node metastases, M1b: bone metastases, M1c: visceral metastases; SBRT: stereotactic body radiotherapy; ADT: androgen deprivation therapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us